S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
ASCENT: sacituzumab govitecan efficacy
Heather McArthur summarizes ASCENT results: PFS and OS benefits of sacituzumab govitecan versus chemotherapy in pretreated TNBC.
Play episode from 06:52
Transcript
